# Neuphoria Therapeutics Inc. (NEUP) · Edgar & Edgarette company card

> Neuphoria Therapeutics (NEUP) saw revenue fall 92.5% in FY2026 to $1 million, operating margin -1401% against a -3.8% median for pharmaceutical preparations, equity 85.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1191070 · fiscal year ended 2026-06-30 · 2 audited years read · [page](https://www.pops4.com/boards/company/NEUP) · [JSON](https://www.pops4.com/boards/company/NEUP.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1M |
| Revenue growth, 1 year | -92.5% |
| Revenue growth per year | — |
| Operating margin | -1401.1% (prior year -7.2%) |
| Net margin | -1145.7% |
| Operating cash flow | −$12M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $20M |
| Long-term debt | — |
| Total assets | $29M |
| Total equity | $25M |
| Equity ÷ assets | 85.7% |
| Return on equity | -54.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -14.7 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating loss: a margin of -1401.1% in FY2026; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $1.2M (FY2026). Experience: revenue down 92.5% on the year; operating margin -1401.1%, down from -7.2%. Soundness: equity 85.7% of assets, return on equity -54.7%. Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $65K and $116K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -1401.1% against a -3.8% median; growth -92.5% against 13.7%.

Range logged 2026-09-21, receipt 10d02c6a3bb9965e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2025-12-18 ([filing](https://www.sec.gov/Archives/edgar/data/1191070/000121390025123289/0001213900-25-123289-index.htm))

## Recent filings

- 8-K · filed 2026-10-23 · 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modifications to Rights of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1191070/000121390026111863/0001213900-26-111863-index.htm)
- DEF 14A · filed 2026-09-18 · [filing](https://www.sec.gov/Archives/edgar/data/1191070/000114036126037139/0001140361-26-037139-index.htm)
- 10-K · filed 2026-09-18 · [filing](https://www.sec.gov/Archives/edgar/data/1191070/000119312526395536/0001193125-26-395536-index.htm)
- 8-K · filed 2026-07-24 · 1.01 Entry into a Material Definitive Agreement; 5.01 Changes in Control of Registrant; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1191070/000121390026081052/0001213900-26-081052-index.htm)
- 8-K · filed 2026-05-26 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1191070/000121390026061028/0001213900-26-061028-index.htm)
- 10-Q · filed 2026-05-15 · [filing](https://www.sec.gov/Archives/edgar/data/1191070/000119312526225442/0001193125-26-225442-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001191070.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1191070

## Cite

POPS4, Edgar & Edgarette: Neuphoria Therapeutics Inc. (NEUP) company card, from the company's own SEC filings, accessed 2026-11-06, https://www.pops4.com/boards/company/NEUP. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.